Search results for

The ads suggest the Affordable Care Act is good for young adults because it'll save them money on health care, leaving them more to spend on liquor and birth control. (This piece initially aired Nov. 24, 2013 on Weekend Edition Sunday).

As nuclear talks with Iran resume, Steve Inskeep talks to Thomas Erdbrink, Tehran bureau chief for The New York Times, about rhetoric and sentiment in that country.

Producer Darren Bagert says there's a boom-or-bust environment on Broadway — you're either a huge hit or you close quickly. Two of the fall's most highly anticipated musicals are closing this month.

Renee Montagne talks to Kevin Grawer, principal of Maplewood Richmond Heights High School, and senior Jazmen Bell, about their efforts to diffuse racial tension and how Ferguson has affected them.

Barbara Ehrenreich — a rationalist, atheist and scientist by training — has written a new memoir called Living With a Wild God: A Nonbeliever's Search for the Truth about Everything.

In a new book, The Dead Sea Scrolls: A Biography, religious scholar and author John J. Collins tells the history of the scrolls and the controversies they have prompted, and explores the questions they ask and answer about Judeo-Christian history.

In Mohsin Hamid's fictional how-to, a nameless protagonist makes a fortune selling knockoff bottled water in a thirsty Asian metropolis. Hamid joins NPR's Steve Inkeep to discuss the book's conceit and the side effects of rampant development.

The housing crisis has taken a toll in Idaho. Home prices dropped by 46 percent in the Boise area and many people lost homes to foreclosure. Before the bubble burst, Charter Pointe became less a neighborhood of neighbors, and more about investor-buyers looking to make money.

The riot appeared to be all chaos and anarchy. But as researchers gave the online video and photos closer scrutiny, they produced forensic evidence that has identified those involved.

While logistical challenges have hampered use of antibody drugs to treat people with mild-to-moderate COVID-19, recent results show the medicines can be worthwhile.